Detalhe da pesquisa
1.
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
N Engl J Med
; 2024 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38820078
2.
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Lancet
; 389(10072): 917-929, 2017 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28126333
3.
Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK + advanced tumors.
Cancer Chemother Pharmacol
; 87(4): 475-486, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33394101
4.
Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers.
Cancer Chemother Pharmacol
; 71(1): 219-26, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23070146
5.
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.
J Cancer Res Clin Oncol
; 139(12): 1985-93, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24057647